Identification of New Patient Stratification Tools in MSS RAS mt mCRC (COLOSSUS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Identification and technical (analytical) validation of new patient stratification tools (COLOSSUS subtypes) in MSS RAS mt mCRC using a novel integrative systems biomedicine multi-omics discovery framework.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All patiens with stage IV MSS RAS mutant colorectal cancer
Ability to give signed informed consent prior to any study specific procedures and willing and able to comply with the protocol
Age ≥ 18 years
ECOG status of ≤ 2
At least 16 weeks of life expectancy at time of entry into the study
Histologically confirmed stage IV MSS RAS mt mCRC as per standard diagnostic tests
Unresectable and measurable disease (at least one measurable target lesion) as per clinical and radiologic criteria (RECIST v.1.1)
No prior chemotherapy for CRC in the metastatic setting, permitted in the neoadjuvant and adjuvant settings
Scheduled to receive SOC chemotherapy with fluoropyrimidines and oxaliplatin +/- bevacizumab
Availability of archival primary tumour tissue block (FFPE) obtained at the time of the initial diagnosis
Patient with rectal cancer that has received any neo-adjuvant therapy before surgical resection of the primary tumour
Patient who has received any investigational product within 28 days of the first day of palliative chemotherapy administration
Patient with any significant history of non-compliance to medical treatments or with inability to grant reliable informed consent
Patient with clinical or laboratory contraindication to receive SOC chemotherapy with fluoropyrimidines and oxaliplatin.